The presentations follow Ashvattha's recent announcement of up to $50 million in additional Series B financing led by Tribe Capital to advance the company's hydroxyl dendrimer therapeutic (HDT) ...
CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene ...
(NYSE: ALIT or “Alight”) today announced it will release fourth quarter and full year 2024 earnings results before market open on Thursday, February 20, 2025, and management will subsequently discuss ...